IAVI to partners to convene international conference on TB vaccine research and development
JANUARY 28, 2020 — Today IAVI, the Stop TB Partnership Working Group on New TB Vaccines (WGNV), the Tuberculosis Vaccine Initiative (TBVI), the Institute of Pharmacology and Structural Biology (IPBS, University Toulouse III-Paul Sabatier), and the French National Centre for Scientific Research (CNRS) announced that the 6th Global Forum on Tuberculosis Vaccines will occur at the Centre Pierre Baudis in Toulouse, France, April 20-22, 2021.
The Global Forum on TB Vaccines is convened every two to three years by the WGNV in collaboration with IAVI, TBVI, and a partner in the host country. The 6th Global Forum is expected to bring more than 300 stakeholders from over 30 countries and all sectors of tuberculosis vaccine research and development to Toulouse. It will allow researchers, clinicians, product developers, policymakers, and patient groups to take stock of advances in the field, exchange perspectives on the latest research and best practices, and define priority actions aimed at accelerating the development of new vaccines against this disease. Previous forums were in Geneva (2001), Tallinn (2010), Cape Town (2013), Shanghai (2015), and New Delhi (2018).
France's application to host the 6th Global Forum on Tuberculosis Vaccines was submitted by the IPBS and the CNRS, with the support of the Federal University of Toulouse Midi-Pyrénées, and was supported by key French research institutes, scientific societies, foundations, and private entities based in France.
Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “IAVI is strongly committed to advancing TB vaccine research, and we are honored to co-organize the 6th Global Forum on TB Vaccines. The Forum will be an important occasion to share cutting-edge research findings, garner support for advancing promising TB vaccine candidates, and for catalyzing the global response to end TB. We are pleased that Toulouse will be hosting the Forum, and are grateful to France for their continued leadership in supporting global health causes.”